Immuron (ASX:IMC) has announced record sales of its over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract, Travelan.
In Australia, sales of Travelan increased to $2.1 million year-to-date January 2024 compared to $300,000 for the corresponding period last year. In the US, for the same period, sales increased to A$600,000 compared to A$300,000.
Immuron also said it has recommenced Travelan sales in Canada through McKesson.
Immuron chief commercial officer Flavio Palumbo said, "We are excited by the strong sales results on Travelan. Immuron's investment to drive awareness of the Travelan brand has seen strong sales results in Australia over the summer peak travel period. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring/summer vacation peak period."
